Fig. 1: Chronic IL1β exposure enhances the expansion of Tet2-KO cells and myeloid bias with the elevation of Ly6chi over Ly6clo monocytes/macrophages. | Nature Communications

Fig. 1: Chronic IL1β exposure enhances the expansion of Tet2-KO cells and myeloid bias with the elevation of Ly6chi over Ly6clo monocytes/macrophages.

From: Clonal hematopoiesis related TET2 loss-of-function impedes IL1β-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells

Fig. 1

ac Lineage-depleted BM cells from wild-type (WT) CD45.1 and Tet2-KO CD45.2 mice were transplanted into WT CD45.1/2 mice which after 3 weeks were treated with IL1β or vehicle daily. a Experimental design, b percentage of WT CD45.1 or Tet2-KO CD45.2 cells out of all CD45+ cells (chimerism, significance shown between Tet2-KO with and without IL1β treatment) and the percentage WT CD45.1 and Tet2-KO CD45.2+ cells which are myeloid in the PB (significance shown between Tet2-KO and WT with IL1β treatment, n = 5 mice/group for Veh, 6 for IL1β) and c myeloid subsets (CD11b+Gr1hi, CD11b+Gr1lo) at week 15 (n = 5 mice/group for Veh, 4 for IL1β). d–f Lineage-depleted BM cells from WT CD45.1+ and Rosa-rtTA-driven inducible Tet2 knockdown (shTet2) CD45.2 mice were transplanted into WT CD45.1+CD45.2+ mice, treated with doxycycline (dox) two weeks after transplantation and IL1β or vehicle three weeks after transplantation for increasing intervals up to 10 weeks and then with and without doxycycline (withdrawal; w/d) for an additional two weeks. Arrows indicate the time relative to the initial treatment (week: 0, 3, 6, 8) and duration (days: 2, 4, 7, and 28) of daily treatment with IL1β or vehicle. Green indicates time and duration of doxycycline treatment. d Experimental design, e percentage of GFP+CD45.2 cells out of donor-derived CD45+ cells and the percentage of WT CD45.1 and shTet2 CD45.2 cells which are myeloid (CD11b+) in the PB for doxy and IL1β or vehicle-treated experimental arms (significance shown between shTet2 and WT with IL1β treatment, right panel, n = 5 mice/group), and f neutrophils (CD11b+Ly6cmidLy6g+), Ly6chi monocytes/macrophages (CD11b+Ly6chiLy6g-), and Ly6clo monocytes/macrophages (CD11b+Ly6cloLy6g-) in the spleen with doxy or without doxy (w/d) for IL1β or vehicle treatments (n = 5 mice/group for Veh, IL1β, Dox w/d IL1β, 4 for Dox w/d mice/group). Error bars represent mean ± SEM. For panels c and f two-factor ANOVA determined family-wise error rate (FWER) adjusted p values. For panels b and e, a student’s two-tailed t-Test determined the significance between single comparisons. For FWER adjusted and regular p values: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Back to article page